Advertisement

Topics

Latest "Daiichi Pharmaceutical" News Stories

08:01 EDT 23rd October 2018 | BioPortfolio

Here are the most relevant search results for "Daiichi Pharmaceutical" found in our extensive news archives from over 250 global news sources.

More Information about Daiichi Pharmaceutical on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Daiichi Pharmaceutical for you to read. Along with our medical data and news we also list Daiichi Pharmaceutical Clinical Trials, which are updated daily. BioPortfolio also has a large database of Daiichi Pharmaceutical Companies for you to search.

Showing "Daiichi Pharmaceutical" News Articles 1–25 of 8,700+

Relevant

Daiichi Sankyo to restructure vaccines subsidiary

Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restructure vaccines subsidiary appeared first on Pharmaceutical Technology.


Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals

Daiichi Sankyo has transferred 41 of its long-listed products to Alfresa Pharma. The transaction also includes products manufactured by Daiichi...Read More... The post Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals appeared first on Pharmaceutical Technology.

Daiichi Sankyo to develop new inflammatory disease drugs

Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs appeared first on Pharmaceutical Technology.


Daiichi Sankyo transfers 41 products to Alfresa Pharma

Daiichi Sankyo has announced plans to split and transfer its inventories to Alfresa Pharma, along with Japanese manufacturing and sales...Read More... The post Daiichi Sankyo transfers 41 products to Alfresa Pharma appeared first on Pharmaceutical Technology.

Deals this week: Twist Bioscience, Kangmei Pharmaceutical, Daiichi Sankyo

Twist Bioscience has completed a private placement of shares to raise $50m. The company plans to use part of the...Read More... The post Deals this week: Twist Bioscience, Kangmei Pharmaceutical, Daiichi Sankyo appeared first on Pharmaceutical Technology.

EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib

Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib...Read More... The post EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib appeared first on Pharmaceutical Technology.

Daiichi Sankyo’s lymphoma therapy gets orphan drug status in Japan

Daiichi Sankyo has secured orphan drug designation from the Japan Ministry of Health, Labour and Welfare (MHLW) for its axicabtagene...Read More... The post Daiichi Sankyo’s lymphoma therapy gets orphan drug status in Japan appeared first on Pharmaceutical Technology.

Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...

TOKYO and MUNICH and BASKING RIDGE, N.J., Oct. 21, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety Read more...

Deals this week: Mylan, Daiichi Sankyo, Takeda

Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries....Read More... The post Deals this week: Mylan, Daiichi Sankyo, Takeda appeared first on Pharmaceutical Technology.

Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

TOKYO, BERLIN, BASKING RIDGE, NJ / ACCESSWIRE / July 30, 2018 / Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive ...

Daiichi's AML drug granted FDA breakthrough status

Daiichi Sankyo's quizartinib, being developed to treat patients with relapsed or refractory acute myeloid leukemia with an FL -More- 

Daiichi to test cancer drug combo

Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.

BRIEF — Daiichi and Kaketsuken end vaccines agreement

Japanese companies Daiichi Sankyo and The Chemo-Sero-Therapeutic Research Institute – known as Kaketsuken…

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an...

Daiichi Sankyo reports on results for leukemia candidate

Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More- 

Daiichi-Merck partnership lines up Keytruda combo therapy

Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significant 39 percent overall response rate (ORR) at week...

#news #biotech Daiichi DMD trial misses primary efficacy endpoint

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Daiichi DMD trial misses primary efficacy endpoint .An early-phase trial of Daiichi Sankyo’s Duchenne muscular dystrophy (DMD) drug has failed to show clear evidence of efficacy. But, buoyed … Continue reading → Cet article #news #biotech Daiichi DMD trial misses...

Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.

Daiichi Sankyo’s Ken Truitt Joins ImmusanT as Chief Medical Officer

Ken Truitt has been appointed chief medical officer of immune drug developer ImmusanT. Truitt comes to the Cambridge, MA, biotech from Daiichi Sankyo, where he was senior vice president for internal medicine therapies. Before joining Daiichi Sankyo, Truitt was director of clinical research in the pulmonary-immunology division of Merck (NYSE: MRK). Last fall, ImmusanT raised […]

Daiichi, Merck subsidiary partner on breast, lung cancer R&D

Daiichi Sankyo and a subsidiary of Merck, known as MSD outside North America, agreed to work together to develop the former's -More- 

New formulation of AZ, Daiichi's Nexium launched in Japan

AstraZeneca and Daiichi Sankyo introduced in Japan its proton pump inhibitor Nexium, or esomeprazole magnesium hydrate, in 10 -More- 

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)

Tokyo, Munich, and Basking Ridge, NJ – (May 8, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib met its primary endpoint of significantly...

Zymeworks and Daiichi Sankyo expand I-O collaboration

Canada’s Zymeworks and Japan’s Daiichi Sankyo have entered into a new license agreement, expanding…

Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201

Daiichi Sankyo Company has signed a clinical trial collaboration agreement with a Merck subsidiary to conduct a Phase lb trial...Read More... The post Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks